ClinicalTrials.gg
TerminatedNCT00776555Updated Jun 9, 2021Results posted

Compare Subjective Drug Liking & Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as an Oral Solution

A Phase 1 interventional study of Lisdexamfetamine Dimesylate and Racemic mixture of dextroamphetamine and lisdexamfetamine in Healthy, sponsored by Shire. Terminated at 1 site in United States. Open to participants aged 18 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-09.

Sponsored by Shire (part of Takeda) · Phase 1, Interventional, and Other

Why this study was terminated
The study was stopped by the sponsor based on a non-safety related business priority decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
18 Years to 25 Years
Sex
All
01

Study summary

The purpose of this study is to compare subjective drug liking using the Drug Rating Questionnaire, subject version (DRQ-S), question 2 and pharmacokinetics of Vyvanse™ and ADDERALL XR® when administered as an oral solution.

Hypothesis: DRQ-S, question 2 will show no difference between the two drugs

Read the detailed description

Not required

02

Conditions studied

  • Healthy

Keywords

  • Not required
03

In context

Lead sponsor

Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.

Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.

First submitted before Shire became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy young adults, male or female (non-pregnant and non-lactating), age 18-25 years at time of consent
  • Have a (BMI) between 20.0 and 29.0kg/m2
  • Satisfactory medical assessment with no or relevant
  • Subject must demonstrate a positive response to amphetamine at Screening

Exclusion criteria

Exclusion Criteria

  • A history of current or recurrent disease that could have an effect on the study
  • Subject has a history of seizures, any tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder
  • Subject has a concurrent chronic or acute illness or other condition that might confound the results of safety assessments or that might increase risk to the subject
  • Subject has any and/or laboratory abnormalities
  • Subject has a documented allergy, or intolerance to amphetamines
  • Subject has been prescribed or has taken amphetamine products in the past, including childhood; recreational use may not be exclusionary per the Investigator's discretion
  • Subject has a known family history of sudden cardiac death or ventricular arrhythmia
  • Subject has a recent history (within the past 6 months) of suspected substance abuse or dependence disorder (excluding nicotine)
  • Subject has participated in any clinical or vaccine trial within 30 days prior to the first dose of study drug
  • Subjects is currently considered a suicide risk, has previously made a suicide attempt or has a prior history of, or is currently demonstrating suicidal ideation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Vyvanse™

    50mg capsule that has been emptied and made into solution

    Drug: Lisdexamfetamine Dimesylate

  • Experimental
    ADDERALL XR®

    20mg capsule that has been emptied, crushed, and made into solution

    Drug: Racemic mixture of dextroamphetamine and lisdexamfetamine

Interventions

  • Study is a two-period cross-over design where subjects will have 2 Screening visits, a Baseline visit, and then be enrolled into the study for 2 Periods. Each Period has 2-3 visits and lasts from 2-6 weeks. At each Period visit subjects will be given one of the two treatment arm drugs that have been solubilized and then have blood drawn for pharmacokinetic analysis and the Drug Rating Questionnaire administered. At the end of Period 1 subjects will be crossed-over to the alternative treatment drug for the Period 2. The Vyvanse™ capsule contents will emptied into water to make a solution and given to subjects to drink at the beginning of each Period visit.

  • DrugRacemic mixture of dextroamphetamine and lisdexamfetamine

    Same visits as described for Vyvanse™. The ADDERALL XR® capsule contents will be crushed, solubilized with water, and given to subjects to drink prior to pharmacokinetic blood draws and DRQ-S administration over the course of two periods.

06

What researchers measure

Primary outcomes

  1. Drug Rating Questionnaire-Subject (DRQ-S), Question 2

    Question 2: How much do you like the effects you are feeling now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.

    Time frame: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12 and 24 hours post-dose

Secondary outcomes

  1. DRQ-S, Question 1

    Question 1: How much do you feel the drug now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.

    Time frame: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12 and 24 hours post-dose

  2. DRQ-S, Question 3

    Question 3: Do you dislike the drug effect you are feeling now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.

    Time frame: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12 and 24 hours post-dose

07

Results

Posted Jul 7, 2010
Limitations and caveats
Shire decided to cancel this study on march 31, 2009 due to changes in business priorities. The study termination was not related to any data or safety concerns.

Participant flow

Shire decided to cancel this study on march 31, 2009 due to changes in business priorities. The study termination was not related to any data or safety concerns.

Participant flow — Overall Study
MilestoneVyvanse FirstADDERALL XR First
Started30
Completed00
Not completed30
Withdrew: Study terminated30

Outcome measures

PrimaryDrug Rating Questionnaire-Subject (DRQ-S), Question 2

Question 2: How much do you like the effects you are feeling now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.

Time frame:
Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12 and 24 hours post-dose

No measurements were reported for this outcome.

SecondaryDRQ-S, Question 1

Question 1: How much do you feel the drug now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.

Time frame:
Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12 and 24 hours post-dose

No measurements were reported for this outcome.

SecondaryDRQ-S, Question 3

Question 3: Do you dislike the drug effect you are feeling now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.

Time frame:
Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12 and 24 hours post-dose

No measurements were reported for this outcome.

Adverse events

Collected over Shire decided to cancel this study on march 31, 2009 due to changes in business priorities. The study termination was not related to any data or safety concerns.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vyvanse First—0/3 (0%)2/3 (66.7%)
ADDERALL XR First———
Most frequent other events
Most frequent other events
EventVyvanse FirstADDERALL XR First
HeadacheNervous system disorders1/3—
Upper respiratory infectionInfections and infestations1/3—

Baseline characteristics

At the time of the premature study termination, only 3 participants had been enrolled into this study. All 3 participants were randomized to receive VYVANSE in Period 1 of this study, and ADDERALL XR in Period 2 of this study. None of the study participants advanced to Period 2, therefore none received ADDERALL XR.

Age, Categorical
Age, Categorical(Participants)Vyvanse FirstADDERALL XR FirstTotal
<=18 years0—0
Between 18 and 65 years3—3
>=65 years0—0
Sex: Female, Male
Sex: Female, Male(Participants)Vyvanse FirstADDERALL XR FirstTotal
Female1—1
Male2—2
Region of Enrollment
Region of Enrollment(Participants)Vyvanse FirstADDERALL XR FirstTotal
United States3—3
08

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2008 to primary completion in Mar 2009, 4 months.

Results were first posted in Jul 2010, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2008
First posted
Oct 21, 2008
StartActual
Nov 21, 2008
Primary completionActual
Mar 31, 2009
CompletionActual
Mar 31, 2009
Results first posted
Jul 7, 2010
Last update
Jun 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00776555
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Oct 21, 2008
Start date
Nov 21, 2008
Primary completion
Mar 31, 2009
Completion
Mar 31, 2009
Results posted
Jul 7, 2010
Last update
Jun 9, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion